CINF (TSX:CINF)) reported its fourth-quarter 2024 earnings with a significant beat on both earnings per share (EPS) and revenue forecasts. The company posted an EPS of $3.14, surpassing the forecasted $1.

Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $3.98 per share, missing the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $4.20 per share a year ago. These figures are adjusted for non-recurring items.